| Name | Title | Contact Details |
|---|---|---|
Kathy Rogers |
Human Resource Director | Profile |
Jonathan Wolin |
Chief of Staff, Chief Compliance Officer and General Counsel | Profile |
Founded in 2013, Aphria is integrating their growing expertise with Health Canada`s new Access to Cannabis for Medical Purposes Regulations (ACMPR) for the medicinal marijuana industry. Possessing greenhouse related growing experience in plant and produce related expertise since 1943, Aphria is positioned to be an industry leader in providing patients with the highest quality medical marijuana. Aphria has developed integrated greenhouse growing solutions specifically focused on quality production of cannabis. With the authorization of quantity scale marijuana growing, Aphria greenhouse operations are a natural fit. Aphria is a licensed producer of Medicinal Marijuana under the Health Canada Regulations. Grown in Greenhouses, Aphria offers premium medical grade cannabis. Located in Leamington in Southwestern Ontario, the heart of the greenhouse-producing sector for plant and produce, Aphria is built from a lengthy background of greenhouse growing and business experience.
Nostrum Laboratories is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Validation & Engineering Group is a Guaynabo, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.